Congress Materials

Medical Information
India
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for India Healthcare Professionals. Would you like to proceed?

I am a healthcare professional registered to practice in IndiaYes, I am a healthcare professional
SelectI am a healthcare professional registered to practice in IndiaYes, I am a healthcare professional
I am a patient/caregiver residing in IndiaNo, go back to the patient portal
SelectI am a patient/caregiver residing in IndiaNo, go back to the patient portal
Non-India residents click here.

Congress Materials

The information on this page pertains to select congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas.
Congress materials may include information for which the product is not approved and/or inconsistent with the product uses described in the Prescribing Information. Pfizer does not suggest or recommend the use of Pfizer Products in any manner other than as described in the Prescribing Information.
Poster
Armstrong AJ, Mottet N, Iguchi T, Szmulewitz RZ, Holzbeierlein J, Villers A, Alcaraz A, Alekseev B, Shore ND, Gomez-Veiga F, Rosbrook B, Zohren F, Lee H-J, Haas GP, Stenzl A, Azad AA June 6, 2022 ASCO 2022 Prostate Cancer

Radiographic Progression in the Absence of Prostate-Specific Antigen (PSA) Progression in Patients With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Post Hoc Analysis of ARCHES

View Presentation View Abstract Plain Language Summary
Poster
Freedland SJ, Klaassen Z, Agarwal N, Sandin R, Leith A, Ribbands A, Clayton E, Butcher J, Gillespie-Akar L, Russell D, Hong A, Ramaswamy K, George DJ June 6, 2022 ASCO 2022 Prostate Cancer

Reasons for Oncologist and Urologist Treatment Choice in Metastatic Castration-Sensitive Prostate Cancer (mCSPC): A Physician Survey Linked to Patient Chart Reviews in the United States

View Presentation View Abstract Plain Language Summary
Poster
Agarwal N, Saad F, Azad AA, Mateo J, Matsubara N, Shore ND, Chakrabarti J, Chen H-C, Lanzalone S, Niyazov A, Fizazi K, for the TALAPRO-3 investigational group June 6, 2022 ASCO 2022 Prostate Cancer

TALAPRO-3: A Phase 3, Double-Blind, Randomized Study of Enzalutamide (ENZA) Plus Talazoparib vs Placebo Plus ENZA in Patients with DDR Gene Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

View Presentation View Abstract Plain Language Summary
Poster
Sharifi N, Azad AA, Patel M, Hearn J, Wozniak M, Zohren F, Sugg J, Haas GP, Stenzl A, Armstrong AJ June 6, 2022 ASCO 2022 Prostate Cancer

The Association of Germline HSD3B1 Genotype With Outcomes in Metastatic Hormone-Sensitive Prostate Cancer Treated with Androgen Deprivation Therapy with or without Enzalutamide (ARCHES)

View Presentation View Abstract Plain Language Summary